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Abstract
Background: Despite improvements in median survival some patients with advanced ovarian cancer die within
100 days of diagnosis; the reasons for which remain poorly understood.
Here we investigate if ultra short-term survival can be explained by patient characteristics or treatment pathways.
Methods: A nested case comparison study was used to examine differences between patients with high grade
serous ovarian/fallopian tube cancer who died within 100 days (n = 28) compared to a comparison group of
patients matched for histology and including any survival greater than 100 days (n = 134).
Results: Cases and comparison patients had similar ages, BMI, ACE-27, deprivation indices, and distribution of
disease on CT. There were no significant delays in time to diagnosis or treatment (p = 0.68) between the groups.
However, cases had lower serum albumin, haemoglobin and higher platelet counts than matched comparison
patients (p < 0.0001) and a worse performance score (P = 0.006).
Conclusion: Patients who die rapidly after a diagnosis of ovarian cancer are only slightly older and have similar pre
treatment frailty compared to patients whose survival approaches the median. However they do appear to undergo
greater physiological compromise as a result of their disease.
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Background
Ovarian cancer is best regarded as a term used to de-
scribe a heterogeneous set of pathologies with mixed
prognosis. Although the overall median survival for
patients with ovarian cancer is approximately 44 months
the range of survival is very wide [1], reflecting the pos-
sible presence of multiple sub groups within this overall
population. Even within the commonest subtype, high-
grade serous cancer (HGSOC), there is heterogeneity in
biology and prognosis [1, 2].
Women who survive less than 2 years from diagnosis
have been termed short term survivors (STS) [2]. How-
ever, there is a small but important group of women
who suffer a very rapid decline, surviving less than 100
days who may be termed ultra short-term survivors
(USTS). With the first line treatment of ovarian cancer
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combining both surgery and chemotherapy, and span-
ning over approximately 150 days, none of the USTS
group, by definition, will complete treatment, and a pro-
portion will never commence treatment at all. The rea-
sons behind this early death are poorly understood, but
this group are important as they could potentially bene-
fit from novel interventions.
The National Cancer Intelligence Network in the UK
identified a group of ultra short-term survivors (USTS)
[3] and showed an association with age, emergency pres-
entation and socioeconomic status, a finding confirmed
by others [4, 5]. Despite a widespread belief that rapid
decline and poor outcome is associated with delays to
both diagnosis and subsequent treatment, there is little
evidence to support this claim. Urban et al. attempted to
identify predictors of very poor outcome in patients with
advanced disease. Patients dying within 90 days of diag-
nosis tended to be older, have increased co-morbidities,
present with stage IV disease, and were less likely to
have accessed specialist care [4]. However, this study
was not conducted within the context of a comprehen-
sive universal care system such as the UK National
Health Sevice (NHS).
We therefore hypothesised that the rapid decline and
death of patients with high-grade serous ovarian cancer
would be attributed to higher levels of background co-
morbidities, and delays in presentation, diagnosis and
treatment compared to patients who survived longer.
We therefore carried out a case comparison study of pa-
tients who died within 100 days of diagnosis (Ultra
short-term survivors (USTS)) matched to a comparison
group made up of patients who survived longer than
100 days.
Methods
We included all patients referred to a tertiary treatment
centre multi disciplinary team (MDT) meeting with
high-grade serous ovarian cancer between 2013 and
2015 inclusive, irrespective of stage, thus including all
patients with ovarian cancer within our geographical
catchment area. All the patients presenting to the MDT
underwent thorough investigation, including imaging,
following national guidance [6]. All cytological and
histological samples were assessed by two independent
consultant histopathologists, one being a specialist in gy-
naecological cancers. All histological samples were
assessed macroscopically, microscopically and under-
went immunohistochemistry staining for p53, WT-1,
oestrogen receptor, PAX-8, CK7 and CK20. In patients
where histology was not available, cytology was used to
make a diagnosis (from ascites or pleural effusions) and
diagnostic methods included immunocytochemistry with
the panel outlined above. In cases where the patient died
before any samples were obtained, the diagnosis was
made on clinical grounds by consensus between consult-
ant radiologists, gynaecological-oncologists and clinical
oncologists, based upon imaging. Patients’ management
was subsequently personalised to offer primary surgery,
neoadjuvant chemotherapy or best supportive care as
appropriate.
The set of patients who died within 100 days of diag-
nosis (ultra short-term survivors, USTS) was identified.
The USTS patients were then matched using a 1:5 ratio
with the remainder of the cohort to generate a compari-
son group. We intentionally only matched for histology
(high-grade serous) to facilitate evaluation of all possible
differences between the two groups. Detailed patient
level data were then collected for all patients. All col-
lected variables were chosen on a pragmatic basis as
likely to represent those data items routinely available to
a treating clinician at the time of presentation, including
those that reflect premorbid background fitness and co-
morbidities, as well those that reflect the impact of dis-
ease. Data items were chosen that have already shown
prognostic significance in other studies of ovarian
cancer.
Patient co-morbidities and baseline clinical characteristics
We collected the patient age, body mass index (BMI),
Adult comorbidity evaluation-27 index (ACE-27) and
index of multiple deprivation score (IMD), at the time of
presentation. These factors were chosen to represent
surrogate markers of general health before onset of dis-
ease, generally defined as “individual effects”. Although
BMI can be affected by the presence of ascites or cach-
exia, it remains a useful marker, especially for extremes
of weight categories. The ACE-27 score quantifies co-
morbidities present at the time of diagnosis. The score
ranges from grade 0 (no comorbidities) to 3 (severe co-
morbidities) [7]. This score does not take into account
the current acute state of the patient, but instead acts as
a background marker of fitness. The IMD score provides
a decile ranking of deprivation for each geographical
area of 1500 residents in the UK, where 1 is the most
deprived and 10 is the least deprived. The score encom-
passes income, employment, education, health, including
access to healthcare, crime, barriers to housing and ser-
vices, and living environment to give an overall marker
of deprivation [8].
Treatment received
The active treatment of high stage high-grade serous
ovarian cancer follows one of two pathways, each includ-
ing both surgery and chemotherapy. Primary debulking
surgery (PDS) followed by six cycles of platinum based
chemotherapy was recommended for patients where
complete cytoreduction was considered feasible. Neoad-
juvant chemotherapy (NACT) with delayed or interval
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debulking surgery (IDS) was recommended for patients
with apparent inoperable disease at presentation.
Treatment pathways were decided, in conjunction with
the patient, by a team comprising six surgical gynae oncol-
ogists and three medical oncologists. For patients treated
at Saint Mary’s, 45% of patients with advanced disease re-
ceive primary surgery and the suboptimal (greater than 1
cm residual disease) cytoreduction rate for patients under-
going surgery during the study period was 7% in both the
primary and the delayed primary setting.
Disease effect
To ascertain the disease burden at the time of presenta-
tion, we recorded the FIGO stage of disease [9], tumour
distribution reported on pre-treatment CT scans, patient
blood parameters, and performance status (PS). These
factors were chosen to represent surrogate markers of
disease burden generally defined as “tumour effects”.
Performance status (PS) is a WHO recognised tool
widely used as a measure of fitness for treatment in on-
cology patients. It is useful to assess the acute fitness of
a patient, but does not take into account co-existing co-
morbidities. It is graded between 0 and 5, 0 being fully
active and 5 being dead [10].
The blood parameters (haemoglobin, platelet, lympho-
cyte, neutrophil, albumin and CA 125) were recorded
for both groups at initial presentation, to avoid any bias
created by clinical intervention, such as blood transfu-
sion. Although median albumin and haemoglobin levels
decrease in an aging population, [11] these effects are
small and given that both groups had very similar age
ranges, no adjustment for age was made. These blood
parameters were also selected as they are a routine part
of the established treatment pathway.
There remains a lack of consensus upon an accurate
way to assess tumour volume or distribution pre-
operatively. Therefore, the diagnostic CT scan reports,
generated by specialist radiologists, were mined to gener-
ate a radiology score, based on presence or absence of dis-
ease in up to 30 anatomical sites, adapted from [12–14],
supplementary Table 1.
Statistics
All data were collected, retrospectively, utilising both
paper and electronic notes, from both referral hospitals,
and tertiary centres. All patient identifiable data were
encrypted so as to maintain confidentiality.
Data were analysed in excel and Graphpad, using
Mann-Whitney U, and T tests to ascertain correlation
between groups.
Results
Between 2013 and 2015 inclusive, 208 patients were di-
agnosed with high grade serous ovarian cancer in our
tertiary unit. 28/208 (13%) died within 100 days of diag-
nosis (ultra short-term survivors, USTS). This group
represented a discrete cohort which is demonstrated, on
a Kaplan-Meier survival curve for the entire patient
population, as a steep initial decline, Fig. 1a,b. One hun-
dred thirty-four patients were then matched by histology
on a 1:5 ratio, from the remainder of the dataset, to gen-
erate the comparison group, Fig. 2.
In the USTS group, 20/28, (71%) received no active
treatment, Fig. 3b. Of the eight patients who did com-
mence active treatment (6/28 PDS, 4/28 NACT), all died
before completion of the treatment pathway. Conversely,
in the comparison group, 131/134 (98%), commenced
and completed first line treatment with 81% of patients
completing six cycles of chemotherapy and undergoing
an operation, the remainder having chemotherapy alone,
Fig. 3c.
In order to ascertain the reasons between the different
treatment patterns in the two groups, we then compared
patient characteristics and disease burden at the time of
presentation, with the aim of identifying delays within
treatment pathways.
Patient co-morbidities and baseline clinical characteristics
Although the USTS group were slightly older than the
comparison group (median age 73 vs 67, p = 0.049) the
range was similar (37–84 vs 37–90) and there were no
significant differences seen between BMI (p = 0.083),
ACE-27 score of co-morbidities (p = 0.34) or deprivation
score (p = 0.27), Table 1. This suggests that the ultra
short-term survivor group, although being slightly older,
are not a cohort of patients who are inherently more
frail. Therefore, the pre-morbid state demographic pa-
rameters have little or no effect upon survival or ability
to receive treatment at the time of presentation.
Patient referral pathway
The tertiary care pathway can be defined as the time
taken by the gynaecological oncology specialist team to
make a diagnosis and formulate a treatment decision,
and includes the time taken for investigations such as
radiology and undertaking biopsies. This time was calcu-
lated and compared between the two groups in order to
establish whether a prolonged pathway could explain
their low levels of active treatment and poor outcome.
There were no significant differences between the two
groups, with the median time taken to make a treatment
decision by the tertiary gynae oncology team being 33
days in the USTS group vs 27 days in the comparison
group (p = 0.68), Fig. 4a.
We calculated the time taken between patient’s pres-
entation to primary care and referral to tertiary care,
seen as ‘pre MDT’, and time taken from first discussion
at MDT to gaining diagnosis or death, seen as ‘post-
Hawarden et al. BMC Cancer          (2021) 21:378 Page 3 of 9
Fig. 1 a Kaplan Meier survival curve for entire cohort in which the initial steep decline identifies patients with ultra short-term survival and (b)
histogram demonstrating a clear incident peak of early deaths
Fig. 2 consort diagram describing the creation of our two distinct groups for comparison from our entire patient population presenting to our
gynaecology MDT with HGSOC over a three year period. The 28 USTS patients represent 13.5% of the ovarian cancer population. The comparison
group were matched by histological grade only (HGSOC) and were randomly selected from our entire patient population
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MDT’. We found no difference between the two groups
for either pre-MDT (p = 0.54) or post-MDT (p = 0.14),
Fig. 4b and c.
When all timelines are combined, and the total time from
initial presentation in primary care to diagnosis/death, there
was no difference between the two groups, Fig. 4d.
Disease effect
Next, we compared the relationship between disease
burden and survival between the two groups, Table 2.
The stage of disease at diagnosis between groups showed
no difference, (7% stage I-II, 93% stage III/IV), with only
slightly more stage IV disease in the USTS group. How-
ever, in both groups the majority of patients presented
at stage III, Table 2.
As a surrogate marker for tumour load, we compared
sites of disease as assessed by CT between groups. There
was no difference in disease distribution between the
groups, either by site of disease, or number of sites in-
volved, even when stratified by stage, suggesting the
USTS group did not have a larger disease burden at the
time of presentation, Table 3.
Finally, we assessed the impact of the disease upon pa-
tient physiology and function using a series of surrogate
markers. The USTS group had poorer performance sta-
tus compared to the comparison group (p = 0.006). Pa-
tients with a worse performance status were less likely
to receive surgical management (21% in USTS vs 73% in
Fig. 3 Sankey diagrams demonstrating the difference in treatment regimens received by each group, including (a) the entire cohort (excluding
11 of the 208 patients for whom treatment was not known). b USTS cases, of whom only 10/28 (36%) commenced treatment, in contrast to (c)
comparison patients. Of whom 131/134(98%) commenced active therapy. Of those that underwent PDS, only four did not receive adjuvant
chemotherapy. Of the 127 patients who underwent chemotherapy, 103 (81%) completed all 6 cycles
Table 1 Pre disease characteristics of cases and controls
r USTS group Comparison group p value
n 28 134
Age (years) Median 73 67 0.049*
Range 37-84 37-90
ACE score Median 1 1 0.337
Range 0-3 0-3
IMD Median 3 4 0.2681
Range 1-9 1-10
BMI Median 25 25 0.832
Range 19-56 17-35
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comparison group), however some patients with low
performance scores did not receive surgery, and some
with high performance scores did receive surgery, sug-
gesting that PS is not the only confounding factor in sur-
gical fitness.
There were also significant differences in blood param-
eters between the groups, with differences in platelet
count, albumin, lymphocyte and neutrophil levels being
significant (p < 0.0001), Table 2. These differences
remained significant when stratified for stage, supple-
mentary Table 1.
Finally, to ensure that these analyses described above
remained valid for all patients, including long term sur-
vivors the control group was divided into patients with
short term survival (STS – 100 days to 2 years) and long
term survivors (LTS – greater than 2 years). This showed
an equivalent number of patients in each group (n = 66
and n = 68 respectively). Small but statistical differences
between the two groups were limited to performance
status, pretreatment lymphocyte count and pretreatment
serum albumin levels, suggesting that the differences
seen between USTS survivors and controls applies to
Fig. 4 a comparison of time taken in the tertiary patient pathway for the two groups, demonstrating no significant difference between the time
taken to reach treatment decision in tertiary care between the USTS group and the comparison group. Patient level bar charts showing time
spent pre and post MDT for each patient in the (b) USTS group and (c) a randomly selected sub cohort (n = 28) of comparison patients. The red
‘pre-MDT’ bar represents time taken from presentation in secondary care to discussion at MDT, with the green ‘post-MDT’ bar representing time
from first discussion to diagnosis/death. d comparison of total time taken from presentation to commencing treatment/death showing no
difference between the timeline in the two groups
Table 2 Disease distribution from CT scans stratified by FIGO









N 28 134 208
Stage (FIGO) I - II 2 (7%) 9 (7%) 26 (13%)
III 16 (57%) 95 (71%) 137 (66%)







I + II Mean no of
sites
1 1 0.6
III Mean no of
sites
3.6 2.9 0.18
IV Mean no of
sites
4.3 3.7 0.35
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both STS and LTS groups equally (supplementary
Table 2).
Discussion
We identified a cohort of patients, comprising 13.5% of
our patients with high-grade serous ovarian cancer, who
die within 100 days of diagnosis, with most not receiving
any form of active treatment, and none completing treat-
ment. Here we attempted, for the first time, to identify if
there were significant clinical differences between those
patients who suffered early demise and did not com-
mence treatment, compared to a comparison group
within the context of a universal health care system in
which all patients were managed within a single clinical
pathway.
Although patients in the USTS group were on average
slightly older, there were no significant differences be-
tween their co-morbidities suggesting that this is not a
group that is inherently frail or unwell prior to the onset
of disease.
Socioeconomic status did not significantly differ be-
tween our cohorts. Although socio-economic status has
been associated with overall survival [4, 5, 15] our data
suggest that this is not an important factor in determin-
ing short term outcome and the commencement of
treatment, at least in the context of a universal health
care system.
Contrary to our hypothesis that the USTS group
would represent a cohort in whom treatment had been
delayed in some way, or who presented late, no signifi-
cant delays were identified within this group. Although
it is well recognised that standards of care and adher-
ence to clinical guidelines are important in determining
outcome [16], our study was a single centre study in
which all patients were managed by a single clinical
pathway. Therefore the USTS group received less treat-
ment, and did especially poorly, despite their care being
determined using identical treatment protocols.
At the time of presentation, the distribution of disease
does not appear to differ between the two groups, thus
refuting the argument that the USTS group fare poorly
due to delayed presentation and therefore more wide-
spread disease and a higher disease burden. In both
groups the majority of patients present at stage III, and
have similar disease distributions, when stratified by
stage. Despite presenting with similar disease distribu-
tion, the USTS are much less likely to receive or
complete treatment.
However, we did show significant differences between
performance status and diagnostic blood parameters.
These parameters are markers of the patient’s biological
and physical response to tumour and are unlikely to be
explained by other factors such as bone metastasis which
occurs in less than 0.5% of patients with high-grade ser-
ous ovarian cancer [17]. This suggests a differing physio-
logical response to disease between the cohorts that
cannot be explained by disease distribution or FIGO
stage. We propose that the differences in the cohorts
may be determined by differences in tumour biology.
Given that this cohort has never been studied in any depth
on a biological level, it is possible there are unique and
thus far unidentified, genomic or other molecular differ-
ences between these tumours. These differences would be
best studied via prospective tissue collection studies.
In this study, given the paucity of tissue samples avail-
able from this cohort we were unable to study the biol-
ogy of the tumours within the USTS group. We were
not even able to comment upon germline BRCA status
as none of the USTS group underwent germline testing,
likely due to insufficient time for genetics referral before
death. These observations highlight the challenges of
studying this group of patients.
Until now identifying these patients to allow recruit-
ment into studies has not been possible and obtaining
histological biopsy for diagnosis that yields sufficient
material for translational studies is difficult. Little is
known regarding the chemotherapy responsiveness of
these tumours as most previous work has been enriched
for patients with a much better prognosis and it is thus
Table 3 Shows comparison of disease effect characteristics
between the ultra short-term survival group and control
patients







Median 2 1 0.006**
Range 0-4 0-3
Hb Mean 115 118 0.1538
Range 92-152 81-148
SD 15 18
Lymphocytes Mean 1.0 1.79 <0.0001 ****
Range 0.37-1.16 0.36-3.67
SD 0 0.76
Neutrophils Mean 10 4.87 <0.0001 ****
Range 4.8-19.3 0.55-20.52
SD 4 2.6
Albumin Mean 28 36 <0.0001 ****
Range 11-43 19-45
SD 8 4.6
Plts Mean 533 313 <0.0001 ****
Range 192-1145 81-714
SD 236 121
CA 125 Mean 2714 939 0.0223*
Range 53-30865 10-12622
SD 5880 1710
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important that translational work is focussed on tu-
mours from patients at high risk of early demise who
may then be able to be included in future clinical trials
of first line therapy and new targeted therapies.
The landscape of ovarian cancer has been refined over
recent years with data from the TCGA and other con-
sortia outlining classifications based on DNA damage re-
pair status [18, 19], mutation profiling [18], gene
expression [20], and copy number changes [21]. Taken
together it is recognised that poor prognosis groups are
associated with tumours with homologous recombin-
ation competency, cyclin E amplification, and specific
copy number signatures. The stromal matrix is also
linked with disease progression in ovarian cancers [22].
What remains unclear however, is whether patients with
USTS have tumours which have a preponderance of
these already established poor prognosis features or
whether they represent a group of tumours with an, as
yet, undescribed biology.
It is hoped that future studies answering these ques-
tions will allow targeted clinical trials to facilitate tailor-
ing of treatment for the patients who, at present, have
the worst prognosis.
Conclusions
A small but significant proportion of patients die rapidly
after a diagnosis of ovarian cancer. Here we have shown
that these patients are neither older nor inherently more
frail than patients whose survival approaches the me-
dian. However they do appear to have disease which
causes greater physiological changes.
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